Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Next Previous
Trial Profile

A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Setidegrasib (Primary) ; Carboplatin; Cetuximab; Cisplatin; Docetaxel; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel; Pembrolizumab; Pemetrexed
  • Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma

Most Recent Events

  • 08 Jan 2026 According to Florida Cancer Specialists & Research Institute media release, data from the trial will be presented at the global ASCO 2025 Gastrointestinal (GI) Cancers Symposium meeting
  • 11 Dec 2025 According to an Astellas Pharma media release, company will present data from this trial at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium, to be held January 8-10, 2026, in San Francisco, California.
  • 18 May 2025 Planned number of patients changed from 541 to 651.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top